An Open-Label, Pharmacokinetic and Tolerability Study of SAR236553/REGN727 Given as a Single SC Dose in Subjects With Mild and Moderate Hepatic Impairment, and in Matched Subjects With Normal Hepatic Function

Trial Profile

An Open-Label, Pharmacokinetic and Tolerability Study of SAR236553/REGN727 Given as a Single SC Dose in Subjects With Mild and Moderate Hepatic Impairment, and in Matched Subjects With Normal Hepatic Function

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Jun 2013

At a glance

  • Drugs Alirocumab (Primary)
  • Indications Hypercholesterolaemia
  • Focus Pharmacokinetics
  • Most Recent Events

    • 01 May 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Jan 2013 Planned end date changed from 1 Feb 2013 to 1 May 2013 as reported by ClinicalTrials.gov.
    • 24 Oct 2012 Planned End Date changed from 1 Aug 2013 to 1 Feb 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top